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Old Saphenous Vein Grafts with Important Degeneration Treated with
Self-Expandable Stents: Our Experience
Cinzia Moncalvo, Vincenzo Puma, Angelo Laurenza, Giuseppe Carosio, Paolo Ciofﬁ
Clinica Città di Alessandria, Alessandria, Italy
BACKGROUND The percutaneous treatment of the coronary saphenous bypass grafts
(SVG) remains a challenge in interventional cardiology. Treatment of degenerated
SVG still involves a high risk of immediate embolic complications, high incidence of
target lesion revascularization and progression of the disease on adjacent segments
and often difﬁculty in the evaluation of the caliber and discrepancy in size in pres-
ence of aneurysm.
AIM to evaluate if the use of self-expandable stents may offer an advantage
compared to balloon-expandable stents. Self-expandable stents may solve the prob-
lem of the discrepancy in size, they can be used in presence of aneurysms or of
widespread disease implying a lower risk of malapposition, with less acute throm-
bosis. They don’t require a heavy post-dilatation implying a lower risk of thrombo-
embolism and parietal damage and leading to a reduced risk of in-stent restenosis,
edge- restenosis and deterioration of adjacent segments. We called this technique
“Soft touch technique” consisting in direct stenting (if possible) and post dilatation
limited to the most stenotic portion of the graft using undersized balloons). Self
expandable stents increase in diameter in the days following the procedure, this may
reduce the incidence of plaque rupture and distal embolization.
RESULTS Between October 2012 and October 2014 we treated 20 patients. 13 with
acute coronary syndrome. Mean age of the grafts: 12 years. In 8 cases we used a distal
embolic protection ﬁlter. 5 patients had aneurysmatic dilatation of the graft. No major
complications occurred. In one case we implanted a balloon expandable stent at distal
edge of self-expandable stent for distal dissection of the vessel with a good ﬁnal
result. In one case we implanted a balloon expandable stent to treat one ostial in-
stent restenosis due to distortion of the stent struts caused by the guiding catheter.
Good angiographic result in all cases (ﬁnal TIMI ﬂow III). CT angiography performed
after 3 months conﬁrmed the patency of the stents. All patients remained asymp-
tomatic during follow-up.
CONCLUSIONS The treatment of degenerated SVG with self-expandable stents and
“soft touch technique” may reduce the risk of distal embolization and of periproce-
dural infarction. This technique, implying a minor parietal trauma, may also reduce
the incidence of restenosis and solve the problem of mismatch of caliber and wide-
spread disease. Larger and appropriate studies are needed to determine differences,
optimize clinical practice and validate our hypothesis.CRT-176
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BACKGROUND Though drug-eluting stents (DES) have shown better outcomes when
compared to bare metal stents (BMS) in patients with native coronary lesions, their
efﬁcacy in saphenous vein graft (SVG) disease is not clear.
METHODS We searched Pubmed, EBSCO and Cochrane databases for terms “drug
eluting stents”, “bare metal stents”, “saphenous vein graft” and their combinations.
Studies with follow up of more than 2 years were included.
RESULTS DES use was associated with signiﬁcant decrease in mortality (odds ratio
(OR) 1.41 p ¼ 0.01), major adverse cardiac events (OR 1.31, p ¼ 0.0003), myocardial
infarction (OR 1.47, p ¼ 0.02), and target vessel revascularization (OR 1.41,
p¼0.006).
CONCLUSIONS DES use is safe and associated with improved long-term outcomes
when compared to BMS in patients with SVG disease.S31THROMBUS MANAGEMENT
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Why Is Demonstrating A Mortality Reduction For New STEMI Therapies
Increasingly Difﬁcult With Conventional RCTs? A Meta-analysis Of 10,375
Patients In Thrombus Aspiration Trials
Daniel Keene, Yousif Ahmad, Darrel Francis
Imperial College Hospitals London, London, United Kingdom
BACKGROUND Thrombus aspiration is a mechanistically logical adjunct therapy to
primary angioplasty for acute myocardial infarction. We use the data from thrombus
aspiration RCTs to quantitatively explore the implications for trialing this and other
therapies, in the modern era of STEMI where highly effective RCT-proven therapy
already provides very low mortality.
METHOD In the ﬁrst part of the study we perform a meta-analysis of RCTs of
thrombus aspiration. In the second part we determine the number of patients that
would be required to deﬁnitively answer the role of thrombus aspiration in the
context of current STEMI mortality rates.
RESULTS All-cause mortality at 30 days or 6-12 months was available in 13 trials
(10,375 patients). At 30 days (10 trials; 9,713 patients) there was no signiﬁcant effect of
thrombus aspiration on all-cause mortality (OR 0.87, 95% CI 0.69-1.11, p¼0.28).
During longer-term follow-up (8 trials; 2,118 patients) there was no statistically sig-
niﬁcant effect of thrombus aspiration on all-cause mortality (OR 0.66, 95% CI 0.41-
1.04, p¼0.08).
Our model demonstrates that to reliably detect a relative risk reduction of 10%,
with a current 30-day mortality of 3% in the control arm of trials, would require
w100,000 patients.
CONCLUSIONS STEMI mortality is now so low that vast numbers of patients are
required to reliably identify the effect of new therapies on mortality. The lack of
statistically signiﬁcant mortality reduction from routine thrombus aspiration in
STEMI is a reﬂection of this. To advance this ﬁeld requires a multi-center trial, with a
patient group several orders of magnitude higher than those currently being
performed.
